|1.||Ueda, Takanori: 4 articles (09/2014 - 02/2010)|
|2.||Nishi, Rie: 4 articles (09/2014 - 02/2010)|
|3.||Yamauchi, Takahiro: 4 articles (09/2014 - 02/2010)|
|4.||Uzui, Kanako: 2 articles (09/2014 - 01/2014)|
|5.||Gandhi, Varsha: 2 articles (03/2008 - 06/2002)|
|6.||Rodriguez, Carlos O: 2 articles (03/2008 - 06/2002)|
|7.||Plunkett, W: 2 articles (04/2001 - 03/2000)|
|8.||Hodge, J P: 2 articles (04/2001 - 03/2000)|
|9.||Keating, M J: 2 articles (04/2001 - 03/2000)|
|10.||Gandhi, V: 2 articles (04/2001 - 03/2000)|
|1.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/2014 - "In the present study, we developed a novel ara-G-resistant variant (CEM/ara-G) of human T-lymphoblastic leukemia cell line CCRF-CEM, and elucidated its mechanism of ara-G resistance. "
09/01/2014 - "T-Lymphoblastic leukemia cell line CCRF-CEM and ara-G-resistant CEM variant cell line CEM/ara-G that we had previously established were used. "
10/01/1999 - "9-Beta-D-Arabinosylguanine (ara-G) is a recently introduced and effective treatment for T-cell acute lymphoblastic leukemia, but how ara-G and ara-G triphosphate (ara-GTP) kill cells is not known. "
09/01/2006 - "Nelarabine (2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine), a synthesised guanosine nucleoside and water-soluble prodrug of ara-G (9-beta-D-arabinofuranosylguanine), has recently been approved by the FDA for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma in adults and children. "
08/25/2011 - "Forodesine and ara-G cytotoxicities were higher in T-cell acute lymphoblastic leukemia (T-ALL) samples than in B-cell precursor (BCP)-ALL and acute myeloid leukemia (AML) samples. "
09/01/2014 - "In the present study, we investigated the cytotoxicity of forodesine in vitro using ara-G-resistant leukemia cells. "
05/01/2007 - "The excellent CSF penetration of nelarabine and ara-G supports further study of the contribution of nelarabine to the prevention and treatment of CNS leukemia."
08/25/2011 - "In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia."
04/01/2013 - "Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line."
03/01/2008 - "Pharmacokinetics of plasma nelarabine and arabinosylguanine (ara-G) and of cellular ara-G triphosphate (ara-GTP) were similar in the two groups of diagnoses, and the elimination of ara-GTP from leukemia cells was slow (median, > 24 hours). "
|3.||Hematologic Neoplasms (Hematological Malignancy)
11/01/1998 - "The goals of the present study were to evaluate GW506U78, a prodrug of ara-G, against human hematologic malignancies and to determine its pharmacokinetics in plasma and cells. "
04/15/2001 - "A pilot protocol was designed to evaluate the efficacy of fludarabine with nelarabine (the prodrug of arabinosylguanine [ara-G]) in patients with hematologic malignancies. "
06/01/2005 - "Clinical studies evaluating the pharmacokinetics of nelarabine, ara-G, and cellular ara-GTP and use of nelarabine, alone or in combination with other agents for the treatment of hematologic malignancies, were included in this review. "
03/01/2000 - "To characterize the pharmacokinetics of nelarabine (506U78), the water-soluble prodrug of 9-beta-D-arabinofuranosyl guanine (ara-G), and ara-G in pediatric and adult patients with refractory hematologic malignancies. "
06/01/2005 - "To present the pharmacology and pharmacokinetics of nelarabine, 9-beta-D-arabinofuranosylguanine (ara-G) and intraleukemic cellular pharmacokinetics of 9-beta-D-arabinofuranosylguanine triphosphate (ara-GTP) generated from the administration of nelarabine, and clinical and safety information relative to nelarabine use in the treatment of hematologic malignancies. "
|4.||Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
|5.||T-Cell Leukemia (Leukemia, T Cell)
|3.||triphosphoric acid (triphosphate)